Acitretin
- Atc Codes:D05BB02
- CAS Codes:55079-83-9
- PHARMGKB ID:55079-83-9
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Neotigason; Belgium: Neotigason; Bulgaria: Neotigason; Cyprus: Neotigason; Czech Republic: Neotigason; Denmark: Neotigason; Estonia: Neotigason; Finland: Neotigason; France: Soriatane; Germany: Neotigason; Greece: Neotigason; Hungary: Neotigason; Ireland: Neotigason; Italy: Neotigason; Latvia: Neotigason; Lithuania: Neotigason; Luxembourg: Neotigason; Malta: Neotigason; Netherlands: Neotigason; Poland: Neotigason; Portugal: Neotigason; Romania: Neotigason; Slovakia: Neotigason; Slovenia: Neotigason; Spain: Neotigasón; Sweden: Neotigason; UK: Neotigason.
North America
Canada: Soriatane; USA: Soriatane.
Latin America
Argentina: Neotigasón; Brazil: Neotigason; Mexico: Neotigasón.
Drug combinations
Chemistry
Acitretin: C~21~H~26~O~3~. Mw: 326.43. (1) 2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (all-E)-; (2)(all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid. CAS-55079-83-9 (1987).
Pharmacologic Category
Antipsoriatic Agents; Retinoid-Like Compounds. (ATC-Code: D05BB02).
Mechanism of action
Therapeutic use
Treatment of severe psoriasis.
Pregnancy and lactiation implications
Ethanol should not be consumed during treatment or for 2 months after discontinuation (forms a teratogenic metabolite). Use not recommended during lactation.
Unlabeled use
Contraindications
Hypersensitivity to acitretin, other retinoids, or any component of the formulation. Use during pregnancy. Ethanol ingestion. Severe hepatic or renal dysfunction. Chronically-elevated blood lipid levels. Concomitant use with methotrexate or tetracyclines.
Warnings and precautions
Risk of depression (including thoughts of self-harm). Use with caution in mental illness. Changes in hepatic transaminases may occur. Use with caution in patients at risk of hypertriglyceridemias. Lipid changes (increased triglycerides, increased cholesterol, and decreased HDL) may occur. Visual changes (decrease in night vision or decreased tolerance to contact lenses) are possible.